Would GSK be looking at discovery research and development or contract research from India?
India has a lot of potential in R&D and pharma. But we are waiting and watching the IPR (intellectual property rights) implementation in India. Other countries such as China are competing for contract and clinical research. If there is a friendlier IPR regime where it is more cost-effective and stricter IPR norms, multinationals are bound to go there. However, India has a huge strength in chemistry and this has been acknowledged worldwide. We are talking to a number of Indian companies to understand their skills in R&D, focus and capabilities. Wherever opportunity exists, we will partner with Indian companies on R&D. The partnership might be on pre-clinical or what they call as proof of concept or in isolated cases; it could go up to Phase-I of clinical trials. Then development has to be done on a large scale for the global market and in terms of infrastructure and marketing, Indian companies may not have the adequate resources today. This is where the parent company GSK could help. We
Related Questions
- If the fee for service contract is on behalf of a research account - is the Office of Research and Development (ORD) involvement required? When does the AVC Deans Office become involved?
- Would GSK be looking at discovery research and development or contract research from India?
- Does the required education apply to Research and Development contract awards?
